CELADON PHARMACEUTICALS PLC

AGM Information • Jul 1, 2025

National Storage Mechanism | Additional information

RNS Number : 1723P

Celadon Pharmaceuticals PLC

01 July 2025

1 July 2025

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Result of Annual General Meeting

Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, announces that at its Annual General Meeting held yesterday, all resolutions were duly passed.

Full details of the poll results are set out below.

Resolutions		Number of votes "For"	% of votes "For"	Number of votes "Against"	% of votes "Against"	Number of votes "Withheld"
1	To re-elect Alexander Anton as a Director	1,380,743	59.95	922,517	40.05	78,362
2	To re-elect James Short as a Director	2,362,865	99.40	14,265	0.60	4,492
3	To reappoint RSM UK Audit LLP as auditors	1,459,118	99.49	7,412	0.51	915,092
4	To authorise the Audit Committee to fix the auditors remuneration	1,457,467	99.32	9,923	0.68	914,232
5	To authorise the directors to allot shares (section 551 Companies Act 2006)	1,453,992	98.99	14,886	1.01	912,744
6	Disapplication of pre-emption rights (section 570 Companies Act 2006)	1,381,713	99.09	12,661	0.91	987,248
7	Disapplication of pre-emption rights (section 570 Companies Act 2006) - further disapplication	1,095,930	98.46	17,176	1.54	1,268,516

The Board acknowledges that resolution 1 received over 20% of votes against. The Board notes the low turnout of shares that voted as a percentage of the Company's issued share capital of 68,845,807 ordinary shares. The board will engage with those shareholders that voted against the resolution to understand the reason behind the voting.

The Board also notes today's announcement by the Company regarding the entry into a debt facility and receipt of the £1.0 million of funds expected within three days, and that following receipt of such funds, the Company intends to proceed with a delisting.

The Board also notes Mr. Anton's previous statement in the Company's 24 March 2025 announcement, that he intends to review his position as Chairman of the Company following the result of the cancellation general meeting, and that in the event that the cancellation of trading of the Company's ordinary shares on AIM is approved, Mr. Anton anticipates he will resign from the board.

Enquiries:

Celadon Pharmaceuticals Plc
James Short	Via Canaccord Genuity Limited
Canaccord Genuity Limited (Nominated Adviser and Broker)
Bobbie Hilliam / Andrew Potts	+44 (0)20 7523 8000
Global Investment Strategy UK Limited (Joint Broker)	+44 (0)20 7048 9400
James Sheehan

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines . Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGPKDBDOBKKFOK